BioSpace News Archive

Leveraging Best-of-Breed Algorithms for Accuracy in Precision Medicine

There is no one-size-fits-all algorithm for AI that enables drug developers to quickly identify the features they seek. Instead, researchers are selecting best-of-breed algorithms for customized analytics.

September 13, 2022
·
5 min read
·
Gail Dutton
Business

Sarepta and Alnylam Seek New Funding Amidst Big Pushes

Sarepta Therapeutics and Alnylam Pharmaceuticals have announced the pricing of $1 billion and $900 million in convertible senior notes respectively.

September 13, 2022
·
2 min read
·
Mark Terry
Rising Patient Awareness of Rare Disorders and Better Healthcare Are Expected to Drive Glycogen Storage Disease Market Growth over the Forecast Period of 2030

The latest market analysis report published by Reports and Data, titled ‘Global Glycogen Storage Disease Market – Forecast to 2030,’ thoroughly examines the Glycogen Storage Disease industry to provide essential data & information for the targeted readers.

September 13, 2022
·
6 min read
Drug Development

Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches

BMS validated LAG-3 as the newest checkpoint in immuno-oncology in March. Regeneron, Merck and Immutep S.A. have been working hard to develop the next successful LAG-3 inhibitor.

September 13, 2022
·
5 min read
·
Heather McKenzie
Business

Rubius Returns to Starting Board, Dismisses 75% of Staff

Rubius is undertaking another restructuring focused on its Red Cell Therapeutics technology that will result in the termination of 75% of its staff and a return to a preclinical starting board.

September 13, 2022
·
3 min read
·
Alex Keown
ESMO 2022: Scientists Isolate Link between Pollution and Lung Cancer

Scientists from the Francis Crick Institute and University College London say they have, for the first time, conclusively explained how air pollution leads to lung cancer in nonsmokers.

September 13, 2022
·
2 min read
·
Paul Elias
Drug Development

Akero Surges on Potentially “Foundational” NASH Data

Akero Therapeutics announced its mid-stage drug candidate, efruxifermin improved liver fibrosis and prevented disease worsening in patients with NASH.

September 13, 2022
·
3 min read
·
Alex Keown
Policy

Biden Vows to Fund Biotech to Fight Cancer on 60th “Moonshot” Anniversary

Pres. Joe Biden vowed to bolster the U.S. biotechnology sector after signing an executive order to improve the fight against cancer.

September 13, 2022
·
1 min read
·
Paul Elias
Drug Development

Is Amgen’s NSCLC Data Enough to Maintain Market Leadership?

Amgen presented data from its Phase III CodeBreaK 200 trial of Lumakras showing the drug improved progression-free survival and objective response rate over intravenous chemotherapy.

September 13, 2022
·
2 min read
·
Mark Terry
Employer Resources

How Employee Resource Groups Strengthen Your DEI Initiatives

Employee Resource Groups (ERGs) can be an asset to any successful Diversity, Equity and Inclusion (DEI) initiative, as long as they are given the proper resources and guidance.

September 13, 2022
·
5 min read
·
Rosemary Scott